PR Newswire
03 Aug 2022, 15:09 GMT+10
TAIZHOU, China, Aug. 3, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Company", together with its subsidiaries, the "Group",Stock code:02179.HK) is pleased to announce that, the Company has recently received the clinical trial approval for its recombinant protein COVID-19 vaccine, ReCOV from the Food and Drug Administration of the Philippines, approving the Company to conduct a randomized, blinded, active-controlled Phase II clinical trial of ReCOV on healthy subjects aged 18 years or above who have received primary vaccination with two doses of an inactivated COVID-19 vaccine to compare the immunogenicity and safety between ReCOV and Pfizer's mRNA vaccine COMIRNATY. The Company plans to commence clinical enrollment in the near future.
ReCOV is a recombinant COVID-19 vaccine being developed by the Company with its technology platforms including the novel adjuvant and protein engineering platforms, and the adjuvant used therein is the Company's self-developed novel adjuvant BFA03. Based on the relevant studies conducted by the Company, ReCOV can induce high titers of neutralizing antibody and Th1 biased cellular immune responses, and has shown favorable neutralizing effect and immune persistence against variants including Omicron variant and Delta variant. It has a variety of comprehensive advantages, including overall positive safety profile, potential growth in production scale, low production cost, preparation stability, and ability to be stored and transported at room temperature.
About Recbio
Founded in 2012, Recbio is an innovative vaccine company. With the vision of "Become the Leader of Innovative Vaccine in the Future," Recbio takes "Protect Human Health with Best-in-Class Vaccines" as its mission. It has established three major cutting-edge technology platforms including novel adjuvants platform, protein engineering platform, immunological evaluation platform and mRNA vaccine platform. Recbio has a high-value vaccine portfolio consisted of HPV vaccine candidates, COVID-19 vaccine candidates, shingles vaccine candidates, influenza vaccine candidates, adults TB vaccine candidates etc. The core management team has more than 20 years of experience in the development and commercialization of innovative vaccines. For more information, please visit https://www.recbio.cn/.
Forward-looking statements
This Presentation may contain projections, estimates, forecasts, targets, opinions, prospects, results, returns and forward-looking statements with respect to the financial condition, results of operations, capital position, strategy and business of the Group which can be identified by the use of forward-looking terminology such as "may", "will", "should", "expect", "anticipate", "project", "plan", "estimate", "seek", "intend", "target", "believe", "potential" and "reasonably possible" or the negatives thereof or other variations thereon or comparable terminology (collectively, "forward-looking statements"), including the strategic priorities, research and development projects, and any financial, investment and capital targets and any other targets, commitments and ambitions described in writing or verbally herein. Any such forward-looking statements are not a reliable indicator of future performance, as they may involve significant stated or implied assumptions and subjective judgements which may or may not prove to be correct, accurate or complete. There can be no assurance that any of the matters set out in the forward-looking statements are attainable, will actually occur or will be realised or are complete or accurate. The assumptions and judgments may prove to be incorrect, inaccurate or incomplete, and involve known and unknown risks, uncertainties, contingencies and other important actors, many of which are outside the control of the Group. There is also no assurance that the Group may develop or market its core products or other pipeline candidates successfully. Actual achievements, results, performance or other future events or conditions may differ materially from those stated, implied and/or reflected in any forward-looking statements due to a variety of risks, uncertainties and other factors (including without limitation general market conditions, regulatory changes, geopolitical tensions or data limitations and changes). Any such forward-looking statements are based on the beliefs, expectations and opinions of the Group at the date the statements are made, and the Group does not assume, and hereby disclaims, any obligation or duty to update, revise or supplement them if circumstances or management's beliefs, expectations or opinions should change. For these reasons, you should not place reliance on, and are expressly cautioned about relying on, any forward-looking statements. No representations or warranties, expressed or implied, are given by or on behalf of the Group as to the achievement or reasonableness of any projections, estimates, forecasts, targets, commitments, prospects or returns contained herein.
Please refer to the announcements published by the Company on the websites of The Stock Exchange of Hong Kong Limited (www.hkexnew.hk) or of the Company (www.recbio.cn) for further details. If there is any inconsistency between this Presentation and the announcements, the announcements shall prevail.
Jiangsu Recbio Technology Co., Ltd.
Investor Inquiry:
Email: ir@recbio.cn
Tel: +86-0523-86818860
Media Inquiry:
Email: media@recbio.cn
Tel: +86-0523-86818860
Related Links:
https://www.recbio.cn/
SOURCE Jiangsu Recbio Technology Co., Ltd.
Get a daily dose of Asia Pacific Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Asia Pacific Star.
More InformationDHAKA, Bangladesh On Thursday, Information Minister Hasan Mahmud said the United Nations Human Rights Council (UNHRC) should focus on Palestine ...
HANOI, Vietnam: The lawyer for prominent social commentator Le Van Dung has reported that a Vietnamese court rejected his appeal ...
DHAKA, Bangladesh - Michelle Bachelet has urged the Bangladesh government to establish an independent investigation into allegations of enforced disappearances. ...
LONDON, England: Despite a legal challenge in London's High Court in early September, the UK government is continuing to pursue ...
MON STATE, Myanmar - According to a statement released by the Karen National Union (KNU) on Sunday, current military strikes ...
NEW DELHI, India: During his national day address this week, Prime Minister NarendraModi said India will seek to become a ...
NEW YORK CITY, New York: Months after the U.S. faced acute shortages of baby formula, this week two major U.S. ...
SYDNEY, NSW, Australia - Stocks were in the doldrums in Asia on Friday as investors weighed up potential Federal Reserve ...
LONDON, England: As surging food costs are further squeezing household budgets, inJuly consumer price inflation in the UK jumped to ...
NEW DELHI, India: After a decline in prices reaching a 2-year low encouraged investors to purchase silver in 2022, India's ...
NEW YORK CITY, New York: The American hedge fund Third Point has purchased a stake worth some $1 billion in ...
NEW YORK, New York - Investors were divided on Thursday as to where to send U.S. stocks. Jitters about inflation, ...